• Moderna launched a private placement of USD 2 billion Convertible Senior Notes due 2032, marketed to qualified institutional buyers.
• An option allows initial purchasers to buy up to an additional USD 300 million of notes within 13 days of issuance.
• Net proceeds earmarked for capped call transactions, general corporate purposes, oncology investment flexibility, debt repayment.
• Notes are senior unsecured, zero-coupon, non-accreting; settlement on conversion may be cash, shares, or a mix.
• Capped call cap price set at least 150% above the stock price at pricing, aiming to limit dilution from conversions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-378505), on September 01, 2026, and is solely responsible for the information contained therein.